Published in Am J Respir Crit Care Med on June 01, 2001
Failure and Cardiovascular Events in Community-acquired Pneumonia (FAILCAP) | NCT01143155
Retrospective Review on Patients With Culture Negative Empyema | NCT04477980
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax (2003) 9.54
Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med (2008) 3.44
Updated review of blood culture contamination. Clin Microbiol Rev (2006) 3.16
Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med (2012) 2.38
Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia. Crit Care Med (2009) 2.32
Impact of clinical practice guidelines on the clinical microbiology laboratory. J Clin Microbiol (2004) 2.25
Emerging resistance among bacterial pathogens in the intensive care unit--a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob (2004) 2.24
The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res (2005) 2.18
Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis (2007) 2.11
Do hospitals provide lower quality of care to black patients for pneumonia? Crit Care Med (2010) 2.07
Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection. BMC Microbiol (2008) 1.98
Methicillin-resistant staphylococcus aureus and community-acquired pneumonia: an evolving relationship. Clin Infect Dis (2012) 1.97
Effects of the Premier Hospital Quality Incentive Demonstration on Medicare patient mortality and cost. Health Serv Res (2009) 1.94
Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax (2004) 1.93
Biodiversity of amoebae and amoeba-resisting bacteria in a hospital water network. Appl Environ Microbiol (2006) 1.80
Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med (2011) 1.77
Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev (2007) 1.74
Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis (2005) 1.74
Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care (2006) 1.70
Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med (2005) 1.69
Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis (2005) 1.68
Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis (2005) 1.64
Screening for lung cancer using low dose CT scanning. Thorax (2004) 1.64
A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax (2006) 1.62
Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J (2004) 1.55
The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax (2006) 1.53
Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis (2006) 1.52
Does hospital performance on process measures directly measure high quality care or is it a marker of unmeasured care? Health Serv Res (2007) 1.49
Tensions in antibiotic prescribing: pitting social concerns against the interests of individual patients. J Gen Intern Med (2002) 1.47
Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc (2014) 1.42
Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis (2002) 1.41
Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest (2009) 1.40
Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax (2003) 1.40
Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. Qual Saf Health Care (2007) 1.36
Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax (2006) 1.35
Variability in processes of care and outcomes among children hospitalized with community-acquired pneumonia. Pediatr Infect Dis J (2012) 1.33
Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother (2003) 1.32
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother (2002) 1.30
In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother (2004) 1.30
Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob (2008) 1.29
Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis (2003) 1.28
Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care (2009) 1.27
Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2006) 1.26
Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ (2006) 1.22
Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung (2007) 1.19
Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care (2007) 1.19
Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest (2009) 1.17
Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care (2010) 1.17
Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis (2011) 1.15
The multidimensional prognostic index predicts short- and long-term mortality in hospitalized geriatric patients with pneumonia. J Gerontol A Biol Sci Med Sci (2009) 1.15
Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis (2003) 1.15
Epidemiology and Ecology of Opportunistic Premise Plumbing Pathogens: Legionella pneumophila, Mycobacterium avium, and Pseudomonas aeruginosa. Environ Health Perspect (2015) 1.14
Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother (2007) 1.14
Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res (2007) 1.14
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med (2009) 1.13
Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med (2009) 1.12
Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res (2009) 1.12
Rapid screening of topoisomerase gene mutations by a novel melting curve analysis method for early warning of fluoroquinolone-resistant Streptococcus pneumoniae emergence. J Clin Microbiol (2006) 1.11
Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care (2012) 1.09
The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. Crit Care (2005) 1.09
Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis. Antimicrob Agents Chemother (2003) 1.08
Physician awareness and self-reported use of local and national guidelines for community-acquired pneumonia. J Gen Intern Med (2003) 1.08
Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care (2013) 1.07
National study of antibiotic use in emergency department visits for pneumonia, 1993 through 2008. Acad Emerg Med (2012) 1.05
4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study. Crit Care (2010) 1.05
Early recognition of the 2009 pandemic influenza A (H1N1) pneumonia by chest ultrasound. Crit Care (2012) 1.03
Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis (2004) 1.02
Antibiotic treatment and survival of nursing home patients with lower respiratory tract infection: a cross-national analysis. Ann Fam Med (2005) 1.02
Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis (2005) 1.01
Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis (2009) 1.01
Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother (2005) 1.01
Limited impact of a multicenter intervention to improve the quality and efficiency of pneumonia care. Chest (2004) 1.01
Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management. Eur J Clin Microbiol Infect Dis (2005) 1.01
Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Respir Res (2013) 1.00
Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care (2012) 1.00
What Is the Clinical Impact of Macrolide Resistance? Curr Infect Dis Rep (2004) 1.00
Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency department. BMC Pulm Med (2009) 0.99
Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother (2006) 0.98
One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System. Int J Infect Dis (2011) 0.97
Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. Epidemiol Infect (2008) 0.97
Testing for coccidioidomycosis among patients with community-acquired pneumonia. Emerg Infect Dis (2008) 0.97
Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis (2011) 0.96
Agreement between emergency physician diagnosis and radiologist reports in patients discharged from an emergency department with community-acquired pneumonia. Emerg Radiol (2005) 0.96
Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis (2005) 0.96
Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care (2012) 0.95
Mycoplasma pneumoniae infection in children is a risk factor for developing allergic diseases. ScientificWorldJournal (2014) 0.95
Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study. Crit Care (2011) 0.95
Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother (2005) 0.93
Sustainability of professionals' adherence to clinical practice guidelines in medical care: a systematic review. BMJ Open (2015) 0.92
Management of kyphoscoliosis patients with respiratory failure in the intensive care unit and during long term follow up. Multidiscip Respir Med (2012) 0.92
Accuracy of Lung Ultrasonography versus Chest Radiography for the Diagnosis of Adult Community-Acquired Pneumonia: Review of the Literature and Meta-Analysis. PLoS One (2015) 0.92
4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia. Anesthesiology (2009) 0.92
Protease-activated receptor-1 impairs host defense in murine pneumococcal pneumonia: a controlled laboratory study. Crit Care (2012) 0.92
Disparities of care for African-Americans and Caucasians with community-acquired pneumonia: a retrospective cohort study. BMC Health Serv Res (2010) 0.92
Quantitative analysis of lung ultrasonography for the detection of community-acquired pneumonia: a pilot study. Biomed Res Int (2015) 0.91
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med (1997) 24.87
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med (2005) 23.85
Bacterial biofilms in nature and disease. Annu Rev Microbiol (1987) 16.14
Medical and dental staffing prospects in the NHS in England and Wales 1993. Health Trends (1994) 13.22
International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J (1995) 13.01
ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med (2005) 11.34
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med (2001) 8.95
ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83
Generation and analysis of 280,000 human expressed sequence tags. Genome Res (1996) 8.27
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis (2000) 7.80
Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology (2001) 6.55
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet (1999) 6.38
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA (1997) 5.85
Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med (1991) 5.85
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med (1994) 5.66
Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med (2004) 5.56
New approach to primary medical care. Nine-point plan for a family practice service. Can Fam Physician (1994) 5.42
Treatment of tuberculosis. MMWR Recomm Rep (2003) 5.41
Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J (2008) 5.38
The C. elegans genome sequencing project: a beginning. Nature (1992) 5.36
Rickettsia africae, a tick-borne pathogen in travelers to sub-Saharan Africa. N Engl J Med (2001) 5.08
Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana. Nature (1999) 5.03
The tuberculin skin test. Clin Infect Dis (1993) 4.89
Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med (1997) 4.84
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med (1993) 4.72
Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis (1998) 4.55
ERD2, a yeast gene required for the receptor-mediated retrieval of luminal ER proteins from the secretory pathway. Cell (1990) 4.54
Professional courtesy--current practices and attitudes. N Engl J Med (1993) 4.52
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis (2000) 4.24
Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med (2000) 4.21
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol (2001) 4.19
Failed intubation revisited: 17-yr experience in a teaching maternity unit. Br J Anaesth (1996) 4.18
Diagnosis of Q fever. J Clin Microbiol (1998) 4.16
Rural background and clinical rural rotations during medical training: effect on practice location. CMAJ (1999) 4.12
Legionellosis. N Engl J Med (1997) 4.12
Fringe is a glycosyltransferase that modifies Notch. Nature (2000) 4.09
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet (1998) 4.05
New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) (1990) 4.04
Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis (2000) 4.01
Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med (1989) 3.98
Cultivation of the bacillus of Whipple's disease. N Engl J Med (2000) 3.97
Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ (2009) 3.95
Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet (1993) 3.89
Scanning and transmission electron microscopy of in situ bacterial colonization of intravenous and intraarterial catheters. J Clin Microbiol (1984) 3.88
Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol (1999) 3.87
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med (2005) 3.82
Proteolytic 18O labeling for comparative proteomics: model studies with two serotypes of adenovirus. Anal Chem (2001) 3.78
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother (1994) 3.73
Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care (1996) 3.70
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis (1993) 3.68
Diagnosis of 22 new cases of Bartonella endocarditis. Ann Intern Med (1996) 3.61
Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis (1994) 3.59
American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med (2003) 3.59
Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep (2005) 3.54
Guidelines for the management of adult lower respiratory tract infections. Eur Respir J (2005) 3.51
The relation of pneumothorax and other air leaks to mortality in the acute respiratory distress syndrome. N Engl J Med (1998) 3.40
Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax (2010) 3.34
Ubiquitousness of Legionella pneumophila in the water supply of a hospital with endemic Legionnaires' disease. N Engl J Med (1982) 3.25
Non-O group 1 Vibrio cholerae gastroenteritis in the United States: clinical, epidemiologic, and laboratory characteristics of sporadic cases. Ann Intern Med (1981) 3.25
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med (2000) 3.09
Serratia marcescens: historical perspective and clinical review. N Engl J Med (1979) 3.08
Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. J Fam Pract (2001) 3.06
Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann Intern Med (1991) 3.04
Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA (1998) 3.03
Pneumonia associated with the TWAR strain of Chlamydia. Ann Intern Med (1987) 3.00
Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect (2011) 2.99
Gastric intramucosal acidosis in mechanically ventilated patients: role of mucosal blood flow. Crit Care Med (1998) 2.99
Bronchopulmonary lavage in man. Ann Intern Med (1965) 2.98
Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J (1999) 2.96
Challenges in end-of-life care in the ICU: statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003: executive summary. Crit Care Med (2004) 2.95
The need for prenatal care in the United States: evidence from the 1980 National Natality Survey. Fam Plann Perspect (1987) 2.93
Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA (1997) 2.91
Isolation of Legionella pneumophila from hospital shower heads. Ann Intern Med (1981) 2.89
How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med (2000) 2.87
Subtypes of Legionella pneumophila serogroup 1 associated with different attack rates. Lancet (1983) 2.87
An Official ATS/AACN/ACCP/ESICM/SCCM Policy Statement: Responding to Requests for Potentially Inappropriate Treatments in Intensive Care Units. Am J Respir Crit Care Med (2015) 2.86
Primary ciliary dyskinesia: diagnosis and standards of care. Eur Respir J (1998) 2.81
Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic. Ann Intern Med (1981) 2.80
Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest (1997) 2.78
Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis (2006) 2.73
Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents (1999) 2.64
Histopathologic and microbiologic aspects of ventilator-associated pneumonia. Anesthesiology (1996) 2.62
Adenovirus stimulation of transcription by RNA polymerase III: evidence for an E1A-dependent increase in transcription factor IIIC concentration. EMBO J (1986) 2.62
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis (1998) 2.61